HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 5 (2008), Issue 8 (August)

1. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma.
   AIDS, 22(13): 1677-9. [Abstract] [Full-text]
2. Herpes simplex virus 2 serostatus and viral loads of HIV-1 in blood and semen as risk factors for HIV transmission among men who have sex with men.
   AIDS, 22(13): 1667-71. [Abstract] [Full-text]
3. Suicidal ideation in UK HIV clinic attenders.
   AIDS, 22(13): 1651-8. [Abstract] [Full-text]
4. HIV prevalence and incidence are no longer falling in southwest Uganda: evidence from a rural population cohort 1989-2005.
   AIDS, 22(13): 1641-9. [Abstract] [Full-text]
5. Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants.
   AIDS, 22(13): 1633-40. [Abstract] [Full-text]
6. Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men.
   AIDS, 22(13): 1615-24. [Abstract] [Full-text]
7. Albendazole treatment of HIV-1 and helminth co-infection: a randomized, double-blind, placebo-controlled trial.
   AIDS, 22(13): 1601-9. [Abstract] [Full-text]
8. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
   AIDS, 22(13): 1583-8. [Abstract] [Full-text]
9. Generation of HIV-1-specific T cells by electroporation of T-cell receptor RNA.
   AIDS, 22(13): 1577-82. [Abstract] [Full-text]
10. Galphai protein-dependant extracellular signal-regulated kinase-1/2 activation is required for HIV-1 reverse transcription.
    AIDS, 22(13): 1569-76. [Abstract] [Full-text]
11. New challenges for mathematical and statistical modeling of HIV and hepatitis C virus in injecting drug users.
    AIDS, 22(13): 1527-37. [Abstract] [Full-text]
12. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms.
    J Biol Chem, 283(32): 22222-32. [Abstract] [Full-text]
13. Immune-driven recombination and loss of control after HIV superinfection.
    J Exp Med, 205(8): 1789-96. [Abstract] [Full-text]
14. The C-type lectin surface receptor DCIR acts as a new attachment factor for HIV-1 in dendritic cells and contributes to trans- and cis-infection pathways.
    Blood, 112(4): 1299-307. [Abstract] [Full-text]
15. Effective suppression of HIV-1 by artificial bispecific miRNA targeting conserved sequences with tolerance for wobble base-pairing.
    Biochem Biophys Res Commun, 374(2): 214-8. [Abstract] [Full-text]
16. The HIV-1 p6/EIAV p9 docking site in Alix is autoinhibited as revealed by a conformation-sensitive anti-Alix monoclonal antibody.
    Biochem J, 414(2): 215-20. [Abstract] [Full-text]
17. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
    J Mol Biol, 381(4): 1000-11. [Abstract] [Full-text]
18. Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition.
    J Mol Biol, 381(4): 956-74. [Abstract] [Full-text]
19. HIV-1 transmission, by stage of infection.
    J Infect Dis, 198(5): 687-93. [Abstract] [Full-text]
20. Relationship between levels of inflammatory cytokines in the genital tract and CD4+ cell counts in women with acute HIV-1 infection.
    J Infect Dis, 198(5): 710-4. [Abstract] [Full-text]
21. Detrimental effects of mannose-binding lectin (MBL2) promoter genotype XA/XA on HIV-1 vertical transmission and AIDS progression.
    J Infect Dis, 198(5): 694-700. [Abstract] [Full-text]
22. Human immunodeficiency virus type 1 nef expression prevents AP-2-mediated internalization of the major histocompatibility complex class II-associated invariant chain.
    J Virol, 82(17): 8373-82. [Abstract] [Full-text]
23. Central role of reverting mutations in HLA associations with human immunodeficiency virus set point.
    J Virol, 82(17): 8548-59. [Abstract] [Full-text]
24. CD4 binding affinity determines human immunodeficiency virus type 1-induced alpha interferon production in plasmacytoid dendritic cells.
    J Virol, 82(17): 8900-5. [Abstract] [Full-text]
25. Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation.
    J Virol, 82(17): 8307-15. [Abstract] [Full-text]
26. Capsid proteins from human immunodeficiency virus type 1 and simian immunodeficiency virus SIVmac can coassemble into mature cores of infectious viruses.
    J Virol, 82(17): 8253-61. [Abstract] [Full-text]
27. Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes.
    J Virol, 82(17): 8422-30. [Abstract] [Full-text]
28. Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly.
    J Virol, 82(17): 8656-63. [Abstract] [Full-text]
29. Impact of mucosal inflammation on cervical human immunodeficiency virus (HIV-1)-specific CD8 T-cell responses in the female genital tract during chronic HIV infection.
    J Virol, 82(17): 8529-36. [Abstract] [Full-text]
30. Higher homologous and lower cross-reactive Gag-specific T-cell responses in human immunodeficiency virus type 2 (HIV-2) than in HIV-1 infection.
    J Virol, 82(17): 8619-28. [Abstract] [Full-text]
31. Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences.
    J Virol, 82(17): 8743-61. [Abstract] [Full-text]
32. Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge.
    Virology, 379(1): 125-34. [Abstract] [Full-text]
33. Suboptimal inhibition of protease activity in human immunodeficiency virus type 1: effects on virion morphogenesis and RNA maturation.
    Virology, 379(1): 152-60. [Abstract] [Full-text]
34. A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients.
    Virology, 379(1): 78-86. [Abstract] [Full-text]
35. Functional domain organization of human APOBEC3G.
    Virology, 379(1): 118-24. [Abstract] [Full-text]
36. Failure to restore the Vgamma2-Jgamma1.2 repertoire in HIV-infected men receiving highly active antiretroviral therapy (HAART).
    Clin Immunol, 128(3): 349-57. [Abstract] [Full-text]
37. Screening of anti-HIV-1 inophyllums by HPLC-DAD of Calophyllum inophyllum leaf extracts from French Polynesia Islands.
    Anal Chim Acta, 624(1): 147-53. [Abstract] [Full-text]
38. A new role for HIV nucleocapsid protein in modulating the specificity of plus strand priming.
    Virology, 378(2): 385-96. [Abstract] [Full-text]
39. Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.
    Virology, 378(2): 272-81. [Abstract] [Full-text]
40. C-type lectin Mermaid inhibits dendritic cell mediated HIV-1 transmission to CD4+ T cells.
    Virology, 378(2): 323-8. [Abstract] [Full-text]
41. Immunity and protection by live attenuated HIV/SIV vaccines.
    Virology, 378(2): 299-305. [Abstract] [Full-text]
42. Relating sequence evolution of HIV1-protease to its underlying molecular mechanics.
    Gene, 422(1): 30-6. [Abstract] [Full-text]
43. High prevalence of unique recombinant forms of HIV-1 in Ghana: molecular epidemiology from an antiretroviral resistance study.
    J Acquir Immune Defic Syndr, 48(5): 599-606. [Abstract] [Full-text]
44. Efficient entry inhibition of human and nonhuman primate immunodeficiency virus by cell surface-expressed gp41-derived peptides.
    Gene Ther, 15(17): 1210-22. [Abstract] [Full-text]
45. MAPPIT (MAmmalian Protein-Protein Interaction Trap) as a tool to study HIV reverse transcriptase dimerization in intact human cells.
    J Virol Methods, 153(1): 7-15. [Abstract] [Full-text]
46. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
    Lancet, 372(9639): 646-55. [Abstract] [Full-text]
47. Ring expanded nucleoside analogues inhibit RNA helicase and intracellular human immunodeficiency virus type 1 replication.
    J Med Chem, 51(16): 5043-51. [Abstract] [Full-text]
48. Novel anti-HIV peptides containing multiple copies of artificially designed heptad repeat motifs.
    Biochem Biophys Res Commun, 374(4): 767-72. [Abstract] [Full-text]
49. Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors.
    J Biol Chem, 283(35): 23599-609. [Abstract] [Full-text]
50. Silencing HIV-1 In Vivo.
    Cell, 134(4): 566-8. [Abstract] [Full-text]
51. Increasing age at HIV seroconversion from 18 to 40 years is associated with favorable virologic and immunologic responses to HAART.
    J Acquir Immune Defic Syndr, 49(1): 40-7. [Abstract] [Full-text]
52. Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study.
    J Acquir Immune Defic Syndr, 49(1): 26-31. [Abstract] [Full-text]
53. Imported malaria in HIV-infected patients enrolled in the ANRS CO4 FHDH study.
    J Acquir Immune Defic Syndr, 49(1): 55-60. [Abstract] [Full-text]
54. Phylogenetic investigation of transmission pathways of drug-resistant HIV-1 utilizing pol sequences derived from resistance genotyping.
    J Acquir Immune Defic Syndr, 49(1): 9-16. [Abstract] [Full-text]
55. Antiretroviral failure despite high levels of adherence: discordant adherence-response relationship in Botswana.
    J Acquir Immune Defic Syndr, 49(1): 107-10. [Abstract] [Full-text]
56. HIV drug resistance pattern among HAART-exposed patients with suboptimal virological response in Ouagadougou, Burkina Faso.
    J Acquir Immune Defic Syndr, 49(1): 17-25. [Abstract] [Full-text]
57. Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand.
    J Acquir Immune Defic Syndr, 49(1): 77-83. [Abstract] [Full-text]
58. CD4 cell response before and after HAART initiation according to viral load and growth indicators in HIV-1-infected children in Abidjan, Côte d'Ivoire.
    J Acquir Immune Defic Syndr, 49(1): 70-6. [Abstract] [Full-text]
59. Genotyping of human papillomavirus DNA in anal biopsies and anal swabs collected from HIV-seropositive men with anal dysplasia.
    J Acquir Immune Defic Syndr, 49(1): 32-9. [Abstract] [Full-text]
60. HIV-1 diversity among inmates of Italian prisons.
    J Med Virol, 80(10): 1689-94. [Abstract] [Full-text]
61. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.
    J Med Virol, 80(10): 1695-706. [Abstract] [Full-text]
62. Inhibition of human immunodeficiency virus-1 entry using vectors expressing a multimeric hammerhead ribozyme targeting the CCR5 mRNA.
    J Gen Virol, 89: 2252-61. [Abstract] [Full-text]
63. The dual role of dendritic cells in the immune response to human immunodeficiency virus type 1 infection.
    J Gen Virol, 89: 2228-39. [Abstract] [Full-text]
64. HIV-1 subtype C Pr55gag virus-like particle vaccine efficiently boosts baboons primed with a matched DNA vaccine.
    J Gen Virol, 89: 2214-27. [Abstract] [Full-text]
65. Classification of hepatitis C virus and human immunodeficiency virus-1 sequences with the branching index.
    J Gen Virol, 89: 2098-107. [Abstract] [Full-text]
66. Induction of the Galpha(q) signaling cascade by the human immunodeficiency virus envelope is required for virus entry.
    J Virol, 82(18): 9191-205. [Abstract] [Full-text]
67. Marked epitope- and allele-specific differences in rates of mutation in human immunodeficiency type 1 (HIV-1) Gag, Pol, and Nef cytotoxic T-lymphocyte epitopes in acute/early HIV-1 infection.
    J Virol, 82(18): 9216-27. [Abstract] [Full-text]
68. Temporal and spatial dynamics of human immunodeficiency virus type 1 circulating recombinant forms 08_BC and 07_BC in Asia.
    J Virol, 82(18): 9206-15. [Abstract] [Full-text]
69. Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase.
    J Virol, 82(18): 9228-35. [Abstract] [Full-text]
70. The broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5.
    J Virol, 82(18): 8986-96. [Abstract] [Full-text]
71. Human immunodeficiency virus type 1 Vif induces cell cycle delay via recruitment of the same E3 ubiquitin ligase complex that targets APOBEC3 proteins for degradation.
    J Virol, 82(18): 9265-72. [Abstract] [Full-text]
72. Preferential cytolysis of peripheral memory CD4+ T cells by in vitro X4-tropic human immunodeficiency virus type 1 infection before the completion of reverse transcription.
    J Virol, 82(18): 9154-63. [Abstract] [Full-text]

© 2004-2010 HIV Research Today. All Rights Reserved.